Details

Autor(en) / Beteiligte

• Wishka, D G
• Graber, DR
• Kopta, LA
• Olmsted, R A
• Friis, J M
• Hosley, J D
• Adams, W J
• Seest, E P
• Castle, T M
• Dolak, LA
• Keiser, B J
• Yagi, Yoshihiko
• Jeganathan, A
• Schlachter, ST

Titel

(-)-6-Chloro-2-[(1-furo[2,3-c] pyridin-5-yl-ethyl)thio]-4-p yrimidinamine, PNU-142721, a New Broad Spectrum HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor

Ist Teil von

• Journal of medicinal chemistry, 1998-04, Vol.41 (9), p.1357-1360

Erscheinungsjahr

1998

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Considerable effort has been focused over the past decade on the development of the HIV-1 specific non-nucleoside reverse transcriptase inhibitors (NNRTIs), due to their desirable safety, selectivity, and antiviral profiles, for the treatment of HIV-1 infection and AIDS. Such efforts at Pharmacia & Upjohn (PNU) have led to the discovery of the bis(heteroaryl)piperazine (BHAP) class of NNRTIs and clinical development of delavirdine. The recent FDA approval of delavirdine (RE-SCRIPTOR) was based on its safety profile and, importantly, its effectiveness in combination with the NRTI AZT. However, a more complete picture of the clinical utility of this NNRTI class of agents awaits the results from triple combination studies.